Metsera came off the board Saturday, leaving Novo Nordisk and others to look elsewhere for next-generation anti-obesity treatments.
The big picture: There are a number of GLP-1 biotechs with drugs around the same stage as Metsera's Phase 2 drugs that could be ripe for an acquisition by Novo or other Big Pharma peers.
